Literature DB >> 34697135

Drug Repositioning With an Anticancer Effect: Contributions to Reduced Cancer Incidence in Susceptible Individuals.

Sungpil Yoon1, Hyung Sik Kim1.   

Abstract

Certain diseases and age groups are associated with a higher incidence of cancer. Cancer prevention can be achieved using repositioned drugs that have anticancer ability, thereby reducing the incidence of cancer in susceptible individuals. This implies that the selection of repositioned drugs can have dual benefits: controlling pre-existing diseases and facilitating cancer prevention. This report outlines the rationale underlying drug repositioning for medications with an anticancer effect and discusses its advantages. We discuss repositioned drugs with anticancer effects that may contribute to cancer prevention in susceptible individuals and the general population with temporary, treatable conditions. The discussion of drug repositioning in this review should facilitate the initiation of clinical trials and lead to therapeutic application of such drugs to reduce the incidence of cancer in susceptible individuals.
Copyright © 2021 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  Drug repositioning; aging; caner prevention; metformin; susceptible individuals

Mesh:

Year:  2021        PMID: 34697135      PMCID: PMC8627728          DOI: 10.21873/invivo.12599

Source DB:  PubMed          Journal:  In Vivo        ISSN: 0258-851X            Impact factor:   2.155


  45 in total

1.  Reversal of multidrug resistance by morning glory resin glycosides in human breast cancer cells.

Authors:  Gabriela Figueroa-González; Nadia Jacobo-Herrera; Alejandro Zentella-Dehesa; Rogelio Pereda-Miranda
Journal:  J Nat Prod       Date:  2011-12-13       Impact factor: 4.050

2.  Co-treatment with Celecoxib or NS398 Strongly Sensitizes Resistant Cancer Cells to Antimitotic Drugs Independent of P-gp Inhibition.

Authors:  Jong Seung Lim; Yujin Park; Byung Mu Lee; Hyung Sik Kim; Sungpil Yoon
Journal:  Anticancer Res       Date:  2016-10-10       Impact factor: 2.480

3.  Tumor vessel normalization by chloroquine independent of autophagy.

Authors:  Hannelore Maes; Anna Kuchnio; Aleksandar Peric; Stijn Moens; Kris Nys; Katrien De Bock; Annelies Quaegebeur; Sandra Schoors; Maria Georgiadou; Jasper Wouters; Stefan Vinckier; Hugo Vankelecom; Marjan Garmyn; Anne-Clémence Vion; Freddy Radtke; Chantal Boulanger; Holger Gerhardt; Elisabetta Dejana; Mieke Dewerchin; Bart Ghesquière; Wim Annaert; Patrizia Agostinis; Peter Carmeliet
Journal:  Cancer Cell       Date:  2014-08-11       Impact factor: 31.743

4.  Co-treatment With HIV Protease Inhibitor Nelfinavir Greatly Increases Late-phase Apoptosis of Drug-resistant KBV20C Cancer Cells Independently of P-Glycoprotein Inhibition.

Authors:  Ji Yeong Kim; Yoo Jung Park; Byung-Mu Lee; Sungpil Yoon
Journal:  Anticancer Res       Date:  2019-07       Impact factor: 2.480

Review 5.  Valproic acid as an adjunctive therapeutic agent for the treatment of breast cancer.

Authors:  Hayley Heers; Jennifer Stanislaw; John Harrelson; Michael W Lee
Journal:  Eur J Pharmacol       Date:  2018-07-31       Impact factor: 4.432

Review 6.  Minocycline as a promising therapeutic strategy for chronic pain.

Authors:  Ya-Qun Zhou; Dai-Qiang Liu; Shu-Ping Chen; Jia Sun; Xiao-Mei Wang; Yu-Ke Tian; Wei Wu; Da-Wei Ye
Journal:  Pharmacol Res       Date:  2018-07-06       Impact factor: 7.658

Review 7.  Development of inhibitors of ATP-binding cassette drug transporters: present status and challenges.

Authors:  Suneet Shukla; Chung-Pu Wu; Suresh V Ambudkar
Journal:  Expert Opin Drug Metab Toxicol       Date:  2008-02       Impact factor: 4.481

8.  Sildenafil potentiates the antitumor activity of cisplatin by induction of apoptosis and inhibition of proliferation and angiogenesis.

Authors:  Mona Mohamed El-Naa; Mohamed Othman; Sheren Younes
Journal:  Drug Des Devel Ther       Date:  2016-11-16       Impact factor: 4.162

9.  Editorial: FDA-Approved Drug Repositioning for P-Glycoprotein Overexpressing Resistant Cancer.

Authors:  Sungpil Yoon; Xiaoju Wang; Sompong Vongpunsawad; Gerard Tromp; Helena Kuivaniemi
Journal:  Front Oncol       Date:  2021-03-17       Impact factor: 6.244

Review 10.  Diabetes and Cancer: Cancer Should Be Screened in Routine Diabetes Assessment.

Authors:  Sunghwan Suh; Kwang Won Kim
Journal:  Diabetes Metab J       Date:  2019-12       Impact factor: 5.376

View more
  2 in total

1.  Contribution of Cancer-Targeting Drugs toward Faster Clinical Application.

Authors:  Sungpil Yoon; Hyung Sik Kim
Journal:  Int J Mol Sci       Date:  2022-06-09       Impact factor: 6.208

2.  Low-Dose Rifabutin Increases Cytotoxicity in Antimitotic-Drug-Treated Resistant Cancer Cells by Exhibiting Strong P-gp-Inhibitory Activity.

Authors:  Ji Sun Lee; Yunmoon Oh; Hyung Sik Kim; Sungpil Yoon
Journal:  Int J Mol Sci       Date:  2022-07-02       Impact factor: 6.208

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.